Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Change in Accured Expenses (2020 - 2025)

BioAtla (BCAB) has disclosed Change in Accured Expenses for 6 consecutive years, with -$747000.0 as the latest value for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 76.49% year-over-year to -$747000.0; the TTM value through Dec 2025 reached $2.8 million, up 120.83%, while the annual FY2025 figure was $2.8 million, 120.83% up from the prior year.
  • Change in Accured Expenses hit -$747000.0 in Q4 2025 for BioAtla, down from $1.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.3 million in Q2 2022 and bottomed at -$9.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $301500.0, with a median of $269000.0 recorded in 2021.
  • Year-over-year, Change in Accured Expenses crashed 2179.49% in 2022 and then surged 229.51% in 2023.
  • BioAtla's Change in Accured Expenses stood at -$2.9 million in 2021, then soared by 74.23% to -$735000.0 in 2022, then plummeted by 886.26% to -$7.2 million in 2023, then surged by 56.17% to -$3.2 million in 2024, then skyrocketed by 76.49% to -$747000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$747000.0, $1.0 million, and $421000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.